VivaBioCell. Delivering next-generation manufacturing solutions for sustainable cell therapies

Certainly, VivaBioCell means innovation.
Thanks to our unique and diversified expertise we are able to provide new tools overcoming the current state-of-the-art in cell culturing and advanced therapy manufacturing.

NANT XL System

The evolution of automated cell expansion systems for mid- up to large-scale batch sizes. Maximum flexibility in cell expansion for clinical and commercial Advanced Therapies manufacturing needs. Learn more >

NANT XL System

NANT 001 System

Seamless transition from R&D to clinical and commercial manufacturing. Automated cell expansion and harvest. Small- to mid-scale batch sizes. Assuring product quality and minimizing costs. Easier cGMP translation and shorter time to market. Ideal for autologous products and redistributed scale-out manufacturing. Learn more >

NANT 001 System

Latest News

NANT 001

The White Paper "Automated Expansion of Adipose-Derived Mesenchymal Stem Cells (AD-MSCs) with NANT 001 System" is now available
The White Paper "Automated Expansion of Adipose-Derived Mesenchymal Stem Cells (AD-MSCs) with NANT 001 System" describes a GMP-compliant process to automatically expand AD-MSCs isolated from fresh adipose tissue using the NANT 001 System, and the results obtained in comparative experiments where the yield, viability and MSCs characterization have been evaluated. Read more ›


Validation of the NANT 001 Bioreactor System for automated adipose-derived MSCs expansion
The results just published by The Regenerative Medicine Institute (REMEDI, Galway, Ireland) show how the NANT 001 System is able to effectively expand autologous MSCs derived from adipose tissue, in aseptic conditions and with a standardized automated process. Read more ›


VivaBioCell is a beneficiary of Immuno-Cluster, a project approved under the Interreg V-A Italy-Slovenia 2014-2020. This Project aims to create a cross-border collaboration among Italian and Slovenian actors and to develop a clinical protocol for the treatment of triple negative breast cancer. Read more ›